期刊
CLINICAL NUCLEAR MEDICINE
卷 48, 期 4, 页码 E165-E166出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RLU.0000000000004513
关键词
immunotherapy; retroperitoneal inflammation; FDG; PET/CT; immune-related adverse effects; pembrolizumab
A 68-year-old man with a history of pulmonary adenocarcinoma on maintenance pembrolizumab presented with new soft tissue stranding and inflammation on F-18-FDG PET/CT, which were confirmed as immunotherapy-related toxicity on biopsy. He discontinued pembrolizumab, which he had been taking for 3 years. Recognizing immunotherapy-related adverse effects on F-18-FDG PET/CT is crucial for timely cessation of treatment.
A 68-year-old man with a history of pulmonary adenocarcinoma on maintenance pembrolizumab presented for surveillance imaging. F-18-FDG PET/CT demonstrated new ill-defined right retroperitoneal and presacral soft tissue stranding with associated FDG uptake suggestive of inflammation. Biopsy results revealed fibroadipose tissue with extensive lymphoplasmacytic inflammation concerning for immunotherapy-related toxicity. The patient was subsequently taken off pembrolizumab, which he had been on for approximately 3 years. Recognition of immunotherapy-related adverse effects and how they can manifest on F-18-FDG PET/CT is important for prompt cessation of treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据